Renal Insufficiency Market Report 2026

Renal Insufficiency Market Overview

• Renal Insufficiency market size has reached to $12.1 billion in 2025 • Expected to grow to $20.51 billion in 2030 at a compound annual growth rate (CAGR) of 11.1% • Growth Driver: Rising Cases Of High Blood Pressure And Diabetes And Their Impact On Kidney Health • Market Trend: Advancements In GLP-1 Receptor Agonists For Managing Diabetes And Chronic Kidney Disease • North America was the largest region in 2025.

What Is Covered Under Renal Insufficiency Market?

Renal insufficiency refers to the reduced ability of the kidneys to filter waste products and maintain fluid and electrolyte balance in the body. It can result from chronic conditions such as diabetes, hypertension, or acute kidney injury, leading to the accumulation of toxins in the blood. If left untreated, renal insufficiency may progress to Chronic Kidney Disease (CKD) or kidney failure, requiring dialysis or transplantation. The main types of treatment for renal insufficiency are medications, dialysis, kidney transplantation, and others. Medications for renal insufficiency include various drugs used to manage symptoms, slow disease progression, or address complications such as high blood pressure, diabetes, and anemia. The various disease stages include chronic kidney disease (CKD) stages and end-stage renal disease (ESRD), and several distribution channels including hospital pharmacies, retail pharmacies, and online pharmacies. The different end-users encompass dialysis centers, hospital and clinics, and research and academic institutes.

What Is The Renal Insufficiency Market Growth Forecast?

The renal insufficiency market size is expected to see rapid growth in the next few years. It will grow to $20.51 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to increasing adoption of home dialysis solutions, rising investments in regenerative therapies, expansion of digital patient monitoring, growing demand for personalized renal treatment plans, increasing focus on slowing disease progression. Major trends in the forecast period include increasing adoption of advanced dialysis modalities, rising focus on early disease stage management, growing use of combination drug therapies, expansion of home-based treatment options, enhanced emphasis on patient-centric care models.

What Is The Driver Of The Renal Insufficiency Market?

The increasing number of high blood pressure and diabetes cases is expected to propel the growth of the renal insufficiency market going forward. Blood pressure and diabetes are attributed to factors such as poor diet, lack of physical activity, obesity, genetic predisposition, and an aging population. High blood pressure damages kidney blood vessels by causing scarring and reduced filtration, while diabetes leads to thickened and overworked kidney vessels due to high blood sugar, with both conditions accelerating kidney damage and leading to renal insufficiency. For instance, in May 2024, according to the National Health Service, a UK-based government agency, in December 2023, the number of high blood pressure diagnoses in the South East increased by 71,120 patients, marking a 5.4% rise compared to December 2022. Further, in April 2023, according to the British Diabetic Association, a UK-based charity organization, 4.3 million people are living with a diabetes diagnosis in the UK. Therefore, the increasing number of high blood pressure and diabetes cases is driving the growth of the renal insufficiency industry.

Key Players In The Global Renal Insufficiency Market

Major companies operating in the renal insufficiency market are Kaiser Permanente, Johnson & Johnson, Roche Holding AG, Sanofi S.A., Abbott Laboratories, Medtronic plc, Amgen Inc., Asahi Kasei Medical Co. Ltd., Fujifilm Holdings Corporation, Fresenius Medical Care, Toray Industries Inc., Baxter International Inc., Boehringer Ingelheim, DaVita Inc., Eisai Co. Ltd., Nipro Corporation, Biocon Limited, HemoCue AB, Rockwell Medical, Mitsubishi Tanabe Pharma Corporation

Global Renal Insufficiency Market Trends and Insights

Major companies operating in the renal insufficiency market are developing glucagon-like peptide-1 receptor agonists (GLP-1 RAs) to address renal and cardiovascular complications in patients with diabetes and chronic kidney disease (CKD). GLP-1 RAs improve glucose control, reduce inflammation, and lower oxidative stress in the kidneys, thereby slowing the progression of renal insufficiency. For instance, in January 2025, Novo Nordisk, a Denmark-based pharmaceutical company, received Food and Drug Administration (FDA) approval for its Ozempic (semaglutide) to reduce the risk of kidney disease worsening, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (CKD). This approval highlights the growing emphasis on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) as a dual approach to managing both diabetes and renal insufficiency, addressing critical unmet needs in patients with progressive CKD.

What Are Latest Mergers And Acquisitions In The Renal Insufficiency Market?

In February 2023, AstraZeneca PLC, a UK-based pharmaceutical company, acquired CinCor Pharma Inc. for $1.8 billion. Through this acquisition, AstraZeneca strengthens its cardiorenal portfolio by incorporating baxdrostat (CIN-107), an aldosterone synthase inhibitor designed to lower blood pressure in treatment-resistant hypertension. CinCor Pharma Inc. is a US-based clinical-stage biopharmaceutical company developing treatments for patients with moderate to severe renal impairment or kidney failure.

What Defines the Renal Insufficiency Market?

The renal insufficiency market consists of sales of dialysis equipment, renal replacement therapies, kidney transplantation services, and pharmaceutical treatments for managing kidney function. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Renal Insufficiency Market Report 2026?

The renal insufficiency market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the renal insufficiency industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.